Interactions between interstitial lung abnormalities and immune checkpoint inhibitor therapy in non-small cell lung cancer: A review of current understanding and future directions.

Hum Vaccin Immunother · 2025 · PMC12080731 · PMID 40366708

Europe PMC DOI

hedged sentence

0.0540

closest p · 1.1× alpha

0.0540

boldest claim

The sentences

showed a trendp = .054so close (0.05 < p ≤ 0.1)

found that the presence of AI-detected ILA showed a trend toward poorer PFS ( p = .054). 30 These findings underscore the necessity for larger-scale studies to elucidate the impact of ILAs on prognosis and clinical outcomes in patients with NSCLC receiving ICIs therapy.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.